JP2022528927A5 - - Google Patents
Info
- Publication number
- JP2022528927A5 JP2022528927A5 JP2021559827A JP2021559827A JP2022528927A5 JP 2022528927 A5 JP2022528927 A5 JP 2022528927A5 JP 2021559827 A JP2021559827 A JP 2021559827A JP 2021559827 A JP2021559827 A JP 2021559827A JP 2022528927 A5 JP2022528927 A5 JP 2022528927A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1905150.7 | 2019-04-11 | ||
| GB1905150.7A GB2589049C (en) | 2019-04-11 | 2019-04-11 | Anti-IgE antibodies |
| PCT/EP2020/060240 WO2020208177A1 (en) | 2019-04-11 | 2020-04-09 | ANTI-IgE ANTIBODIES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528927A JP2022528927A (ja) | 2022-06-16 |
| JP2022528927A5 true JP2022528927A5 (enExample) | 2023-04-18 |
| JP7586833B2 JP7586833B2 (ja) | 2024-11-19 |
Family
ID=66809886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559827A Active JP7586833B2 (ja) | 2019-04-11 | 2020-04-09 | 抗ＩｇＥ抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20220177604A1 (enExample) |
| EP (1) | EP3953396A1 (enExample) |
| JP (1) | JP7586833B2 (enExample) |
| KR (1) | KR20210150430A (enExample) |
| CN (1) | CN113939540A (enExample) |
| AU (1) | AU2020271405A1 (enExample) |
| BR (1) | BR112021020329A2 (enExample) |
| CA (1) | CA3133941A1 (enExample) |
| EA (1) | EA202192785A1 (enExample) |
| GB (1) | GB2589049C (enExample) |
| IL (1) | IL287035A (enExample) |
| MA (1) | MA55600A (enExample) |
| MX (1) | MX2021012457A (enExample) |
| PH (1) | PH12021552545A1 (enExample) |
| SG (1) | SG11202110247XA (enExample) |
| WO (1) | WO2020208177A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| EP4431528A1 (en) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| JP2025523583A (ja) | 2022-07-01 | 2025-07-23 | アルク－アベーロ アクティーゼルスカブ | ＩｇＥ－ＦｃＥＲＩのディスプレーサー |
| CN115724951B (zh) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | 与11型hpv结合的抗体或其抗原结合片段及其应用 |
| CN120882430A (zh) * | 2023-01-18 | 2025-10-31 | 利西亚治疗公司 | 循环溶酶体靶向抗体缀合物 |
| CN118725128B (zh) * | 2023-03-28 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 抗IgE抗体、检测IgE的试剂和试剂盒 |
| CN119490594B (zh) * | 2023-08-15 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
| US20250101111A1 (en) * | 2023-09-07 | 2025-03-27 | argenx BV | Fcrn antagonists and methods of use |
| GB202318512D0 (en) * | 2023-12-04 | 2024-01-17 | argenx BV | Methods of determining potency |
| WO2025229206A1 (en) * | 2024-05-03 | 2025-11-06 | argenx BV | Monovalent anti-iga binding molecules and methods of use |
| US20250353930A1 (en) | 2024-05-17 | 2025-11-20 | Excellergy, Inc. | Antibodies and antibody fragments that bind ige |
| WO2025255496A1 (en) * | 2024-06-07 | 2025-12-11 | Nuvig Therapeutics, Inc. | Modified fc polypeptides |
| WO2026015664A1 (en) * | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002040047A2 (en) | 2000-11-20 | 2002-05-23 | Canadian Blood Services | Method for treating thrombocytopenia with monoclonal ivig |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| CA2512974A1 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Soluble fc.gamma.r fusion proteins and methods of use thereof |
| WO2004070011A2 (en) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| SG11201605203UA (en) * | 2013-12-24 | 2016-07-28 | Argen X N V | Fcrn antagonists and methods of use |
| PL3137504T3 (pl) * | 2014-04-30 | 2023-10-16 | Hanall Biopharma Co., Ltd. | Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych |
| CA2978253A1 (en) * | 2015-03-09 | 2016-09-15 | Argenx Bvba | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| GB201707484D0 (en) | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
-
2019
- 2019-04-11 GB GB1905150.7A patent/GB2589049C/en active Active
-
2020
- 2020-04-09 MX MX2021012457A patent/MX2021012457A/es unknown
- 2020-04-09 WO PCT/EP2020/060240 patent/WO2020208177A1/en not_active Ceased
- 2020-04-09 SG SG11202110247XA patent/SG11202110247XA/en unknown
- 2020-04-09 KR KR1020217034261A patent/KR20210150430A/ko not_active Ceased
- 2020-04-09 EP EP20718649.5A patent/EP3953396A1/en active Pending
- 2020-04-09 AU AU2020271405A patent/AU2020271405A1/en active Pending
- 2020-04-09 PH PH1/2021/552545A patent/PH12021552545A1/en unknown
- 2020-04-09 CA CA3133941A patent/CA3133941A1/en active Pending
- 2020-04-09 CN CN202080038130.8A patent/CN113939540A/zh active Pending
- 2020-04-09 EA EA202192785A patent/EA202192785A1/ru unknown
- 2020-04-09 BR BR112021020329A patent/BR112021020329A2/pt unknown
- 2020-04-09 JP JP2021559827A patent/JP7586833B2/ja active Active
- 2020-04-09 MA MA055600A patent/MA55600A/fr unknown
- 2020-04-09 US US17/598,033 patent/US20220177604A1/en not_active Abandoned
-
2021
- 2021-10-06 IL IL287035A patent/IL287035A/en unknown
-
2025
- 2025-07-02 US US19/258,059 patent/US20250388700A1/en active Pending
- 2025-07-02 US US19/257,976 patent/US20250388699A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022528927A5 (enExample) | ||
| US20250388700A1 (en) | Variant fc regions | |
| ES2932602T3 (es) | Anticuerpos contra la proteína alfa reguladora de señales y métodos de uso | |
| KR20190038607A (ko) | 조작된 폴리펩티드 및 그의 용도 | |
| US20210040200A1 (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| JP2018509413A5 (enExample) | ||
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| CA3214283A1 (en) | Anti-cd19 antibodies and car-t structures | |
| TW202024132A (zh) | Cd200r促效劑抗體及其用途 | |
| CN106574259A (zh) | 新的抗人类Igβ抗体 | |
| US20250188161A1 (en) | TGF-ß ANTIBODIES | |
| WO2026076213A2 (en) | Anti-hsa antibody fusions and methods of use thereof | |
| US20260070982A1 (en) | Antigen binding molecules to cd3 and cd19 | |
| US20240368283A1 (en) | Molecules for modulating the immune system and uses thereof | |
| WO2026077414A1 (en) | ANTIBODIES BINDING IL-7R Alpha AND USES THEREOF | |
| EA049400B1 (ru) | Антитела к ige | |
| HK40058421A (en) | Anti-ige antibodies | |
| EA050049B1 (ru) | Антитела к cd19 и car-t-клеточные структуры | |
| WO2026064650A1 (en) | Pd-1 binding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use | |
| KR20260036311A (ko) | IgG 관련 질환 및 장애의 치료를 위한 개선된 FcRn 길항제 |